Acumen Pharmaceuticals, Inc. (ABOS)

Market Cap	60.57M
Revenue (ttm)	n/a
Net Income (ttm)	-102.33M
Shares Out	60.57M
EPS (ttm)	-1.71
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	125,943
Open	0.980
Previous Close	0.996
Day's Range	0.959 - 1.010
52-Week Range	0.855 - 3.920
Beta	0.09
Analysts	Strong Buy
Price Target	7.33 (+633.0%)
Earnings Date	May 13, 2025

About ABOS

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer’s disease. The company focuses on advancing a targeted immunotherapy drug candidate Sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2, which has completed the INTERCEPT-AD phase 1 clinical trial and in ALTITUDE-AD phase 2 clinical trial to target soluble amyloid-beta oligomers. It has a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of Sa...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jul 1, 2021
• Employees: 61
• Stock Exchange: NASDAQ
• Ticker Symbol: ABOS
• Website: https://acumenpharm.com

Analyst Forecast

According to 3 analysts, the average rating for ABOS stock is "Strong Buy." The 12-month stock price forecast is $7.33, which is an increase of 633.00% from the latest price.

Price Target

$7.33

(633.00% upside)

Analyst Consensus: Strong Buy